Compare Novavax Inc (NVAX) vs Vanguard High Dividend Yield ETF (VYM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Vanguard High Dividend Yield ETF — how do they compare? Novavax Inc trades at $11.11 (market cap $1.82B), while Vanguard High Dividend Yield ETF trades at $158.37 (market cap $100.80B). The key difference: Vanguard High Dividend Yield ETF is far larger — about 55.4× Novavax Inc's market cap, and Vanguard High Dividend Yield ETF is more actively traded (908,176 versus 6,198,505). Which is the better fit depends on your goals — on Pluang, investors hold Novavax Inc for 59 Days and Vanguard High Dividend Yield ETF for 138 Days on average.
| NVAX | VYM | |
|---|---|---|
Market Cap | $1.82B | $100.80B |
Volume | 6,198,505 | 908,176 |
Sector | Health | — |
52-Week High | $12.56 | $167.03 |
52-Week Low | $6.22 | $137.47 |
Typical Hold Time | 59 Days | 138 Days |
Enterprise Value | $1.39B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $11.22, down 0.88% on the day, with a bullish technical signal from moving averages and strong analyst support (74% buy ratings). The company shows mixed fundamentals with a positive P/E of 3.14 and EV/EBITDA of 1.72, but negative net income margin of -59.87% and negative shareholder equity. Recent developments include regulatory approvals for its updated COVID-19 vaccine and strategic pivot toward Matrix-M adjuvant licensing partnerships.
The outlook remains speculative with significant execution risks in the transition from COVID vaccine dependency to partnership-driven model. While valuation metrics appear attractive and technical momentum is positive, persistent negative cash flows and competitive pressures in the biotech sector warrant caution. The stock presents high-risk, high-reward potential for investors comfortable with biotech volatility.
VYM trades at $157.45, down 0.58% with a bearish technical signal. The ETF shows neutral oscillators but bearish moving averages, with support at $157 and resistance at $158. Recent news highlights VYM's consistent dividend yield of 2.42% but notes performance lag versus peers like SCHD and IDV, which have outperformed year-to-date.
VYM faces competition from higher-yielding alternatives and exhibits vulnerability to dividend cuts in its holdings. The ETF's broad diversification provides stability, but investors may seek better returns elsewhere. Key risks include sector concentration and interest rate sensitivity affecting dividend appeal.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Vanguard High Dividend Yield ETF
The advisor employs an indexing investment approach designed to track the performance of the index, which consists of common stocks of companies that pay dividends that generally are higher than average. The advisor attempts to replicate the target index by investing all, or substantially all, of the fund's assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VYM →
